Retatrutide and Muscle Preservation
Retatrutide causes lean mass loss alongside fat loss, consistent with other GLP-1 class drugs. Phase 2 DEXA data confirmed this. The proportion of lean mass lost relative to total weight loss is not fully characterized. Resistance training and adequate protein intake are the primary evidence-based strategies for minimizing lean mass loss.
What Phase 2 Data Shows
Phase 2 DEXA data showed lean mass loss alongside fat loss. At 12 mg (48 weeks), total weight loss was ~24.2%. The composition of that weight loss included both fat mass and lean mass reduction. The exact lean mass percentage is not prominently reported in the primary publication; Phase 3 body composition data is pending peer-reviewed publication.
Why Lean Mass Loss Occurs
Lean mass loss during significant caloric restriction is a well-established physiological phenomenon, not specific to retatrutide. When the body is in a caloric deficit, it draws energy from both fat stores and lean tissue. GLP-1 class drugs produce substantial caloric restriction through appetite suppression, which drives both fat and lean mass loss.
Evidence-Based Strategies for Muscle Preservation
Strong evidence from semaglutide and tirzepatide studies that resistance training attenuates lean mass loss during GLP-1 treatment. Likely applicable to retatrutide but not directly studied.
Higher protein intake during caloric restriction is associated with better lean mass preservation. GLP-1 drugs reduce appetite, which can inadvertently reduce protein intake. Deliberate protein prioritization is important.
Slower weight loss is associated with better lean mass preservation. Retatrutide produces rapid weight loss; the pace may affect lean mass outcomes.
Questions about retatrutide? A licensed physician can review your case.
Start Physician Review